Protagonist Therapeutics (PTGX) Stock Statistics & Valuation Metrics

Protagonist Therapeutics has a market cap or net worth of $8.46B. The enterprise value is $6.98B.

Protagonist Therapeutics has 64,311,370 shares outstanding. The number of shares has decreased by -2.65% in one year.

Protagonist Therapeutics’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -25.23%.

The current PE Ratio of Protagonist Therapeutics is ―. Protagonist Therapeutics’s PEG ratio is 0.29.

In the last 12 months, Protagonist Therapeutics had revenue of 46.02M and earned -130.15M in profits. Earnings per share was -2.05.

In the last 12 months, operating cash flow was -116.64M and capital expenditures 330.00K, giving a free cash flow of -116.31M billion.

Protagonist Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Protagonist Therapeutics upcoming earnings date is Jul 30, 2026, After Close (Confirmed).

Protagonist Therapeutics as a current ratio of 12.71, with Debt / Equity ratio of 1.49%

In the past 12 months, Protagonist Therapeutics has paid 838.00K in taxes.

Protagonist Therapeutics EV to EBITDA ratio is -42.43, with an EV/FCF ratio of 96.90.

Protagonist Therapeutics has $547.79M in cash and marketable securities with $9.78M in debt, giving a net cash position of $538.01M billion.

Gross margin is 99.45%, with operating margin of -343.63%, and net profit margin of -282.83%.

The average price target for Protagonist Therapeutics is $117.78, which is 11.43% higher than the current price. The consensus rating is Strong Buy